Gene expression and soluble protein level of PD-1 and its ligands (PD-L1 and PD-L2) in endometrial cancer.

Autors: Mamat Yusof MN; Department of Obstetrics and Gynaecology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia., Chew KT; Department of Obstetrics and Gynaecology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia., Kampan NC; Department of Obstetrics and Gynaecology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia., Hafizz AMHA; Department of Obstetrics and Gynaecology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia., Shafiee MN; Department of Obstetrics and Gynaecology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.

Font: PloS one [PLoS One] 2025 Mar 05; Vol. 20 (3), pp. e0312765. Date of Electronic Publication: 2025 Mar 05 (Print Publication: 2025).

Tipologia de la publicació: Journal Article

Informació de la publicació: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Terms MeSH: Endometrial Neoplasms*/genetics , Endometrial Neoplasms*/pathology , Endometrial Neoplasms*/metabolism , B7-H1 Antigen*/genetics , B7-H1 Antigen*/metabolism , Programmed Cell Death 1 Ligand 2 Protein*/genetics , Programmed Cell Death 1 Ligand 2 Protein*/metabolism , Programmed Cell Death 1 Receptor*/genetics , Programmed Cell Death 1 Receptor*/metabolism , Gene Expression Regulation, Neoplastic*, Humans ; Female ; Middle Aged ; Aged ; RNA, Messenger/genetics ; RNA, Messenger/metabolism ; Adult

Safety and efficacy of programmed cell death-1 inhibitors in relapsed immune-privileged site lymphoma: A systematic review and meta-analysis.

Autors: Uawithya E; Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand., Kulchutisin K; Department of Transfusion Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand., Jitprapaikulsan J; Division of Neurology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.; Department of Medicine, Division of Neurology, Faculty of Medicine Siriraj Hospital, Mahidol University, Siriraj Neuroimmunology Center, Bangkok, Thailand., Leelakanok N; Division of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Burapha University, Chonburi, Thailand., Owattanapanich W; Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.; Faculty of Medicine Siriraj Hospital, Center of Excellence of Siriraj Adult Acute Myeloid/Lymphoblastic Leukemia, Mahidol University, Bangkok, Thailand.

Font: PloS one [PLoS One] 2025 Apr 29; Vol. 20 (4), pp. e0319714. Date of Electronic Publication: 2025 Apr 29 (Print Publication: 2025).

Tipologia de la publicació: Journal Article; Systematic Review; Meta-Analysis

Informació de la publicació: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Terms MeSH: Immune Checkpoint Inhibitors*/therapeutic use , Immune Checkpoint Inhibitors*/adverse effects , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , Central Nervous System Neoplasms*/drug therapy , Central Nervous System Neoplasms*/immunology , Testicular Neoplasms*/drug therapy , Testicular Neoplasms*/immunology , Testicular Neoplasms*/pathology , Neoplasm Recurrence, Local*/drug therapy , Lymphoma, Large B-Cell, Diffuse*/drug therapy , Lymphoma, Large B-Cell, Diffuse*/immunology, Humans ; Male ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antibodies, Monoclonal, Humanized/adverse effects ; Treatment Outcome

The association of PD-L1 expression status and the PD-1/PD-L1 inhibitor-related toxicity profile in non-small cell lung cancer.

Autors: Zhu Q; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, P.R. China.; Department of Intensive Care Unit, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China., Hu H; Department of Radiation Therapy, General Hospital of Southern Theater Command, Guangzhou, 510000, China., OuYang LY; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, P.R. China.; Department of Intensive Care Unit, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China., Yang R; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, P.R. China.; Department of Intensive Care Unit, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China., Wei WX; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, P.R. China.; Department of Intensive Care Unit, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China., Huang P; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, P.R. China.; Department of Intensive Care Unit, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China., He XR; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, P.R. China. hexr@sysucc.org.cn.; Department of Intensive Care Unit, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China. hexr@sysucc.org.cn.

Font: BMC cancer [BMC Cancer] 2025 Apr 28; Vol. 25 (1), pp. 799. Date of Electronic Publication: 2025 Apr 28.

Tipologia de la publicació: Journal Article; Meta-Analysis

Informació de la publicació: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

Terms MeSH: B7-H1 Antigen*/analysis , B7-H1 Antigen*/antagonists & inhibitors , B7-H1 Antigen*/metabolism , Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/metabolism , Carcinoma, Non-Small-Cell Lung*/pathology , Drug-Related Side Effects and Adverse Reactions*/etiology , Drug-Related Side Effects and Adverse Reactions*/metabolism , Immune Checkpoint Inhibitors*/adverse effects , Immune Checkpoint Inhibitors*/therapeutic use , Lung Neoplasms*/drug therapy , Lung Neoplasms*/metabolism , Lung Neoplasms*/pathology , Programmed Cell Death 1 Receptor*/antagonists & inhibitors, Humans ; Biomarkers, Tumor/metabolism

Thyroid dysfunction as a predictor of PD- 1/PD-L1 inhibitor efficacy in advanced lung cancer.

Autors: Wang Y; Department of Oncology, The First Affiliated Hospital of School of Medicine Shihezi University, Shihezi, Xinjiang, 832000, People's Republic of China., Ma X; Department of Oncology, The First Affiliated Hospital of School of Medicine Shihezi University, Shihezi, Xinjiang, 832000, People's Republic of China., Ma J; Department of General Surgery, Shanghai Jian Gong Hospital, Shanghai, 200083, People's Republic of China., Li J; Department of Oncology, The First Affiliated Hospital of School of Medicine Shihezi University, Shihezi, Xinjiang, 832000, People's Republic of China., Lin Z; Department of Oncology, The First Affiliated Hospital of School of Medicine Shihezi University, Shihezi, Xinjiang, 832000, People's Republic of China., Gao W; Department of Radiotherapy, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, 200434, People's Republic of China. gaowei1977@tongji.edu.cn., Gong P; School of Medicine, Shihezi University, Shihezi, Xinjiang, 832000, People's Republic of China. gongp1122@sina.com., Dai P; Department of Radiotherapy, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, 200434, People's Republic of China. daiping@tongji.edu.cn.

Font: BMC cancer [BMC Cancer] 2025 Apr 28; Vol. 25 (1), pp. 791. Date of Electronic Publication: 2025 Apr 28.

Tipologia de la publicació: Journal Article

Informació de la publicació: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

Terms MeSH: Lung Neoplasms*/drug therapy , Lung Neoplasms*/mortality , Lung Neoplasms*/pathology , Lung Neoplasms*/complications , Immune Checkpoint Inhibitors*/therapeutic use , Immune Checkpoint Inhibitors*/adverse effects , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , B7-H1 Antigen*/antagonists & inhibitors , Thyroid Diseases*, Humans ; Female ; Male ; Middle Aged ; Retrospective Studies ; Aged ; Adult ; Thyrotropin/blood ; Prognosis ; Aged, 80 and over ; Progression-Free Survival

PD-1 inhibitors improve the efficacy of transcatheter arterial chemoembolization combined with apatinib in advanced hepatocellular carcinoma: a meta-analysis and trial sequential analysis.

Autors: Yu J; Department of Hepato-Biliary-Pancrease II, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, 637000, People's Republic of China., Yu J; North Sichuan Medical College, Nanchong, Sichuan, 637000, People's Republic of China., Chen Y; Department of Hepato-Biliary-Pancrease II, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, 637000, People's Republic of China., Yang Y; Department of Educational Technology, Institute of Education, China West Normal University, Nanchong, Sichuan, 637000, People's Republic of China.; Nanchong Gaoping District Wangcheng Primary School, Nanchong, People's Republic of China., Yi P; Department of Hepato-Biliary-Pancrease II, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, 637000, People's Republic of China. 13065256256@163.com.

Font: BMC cancer [BMC Cancer] 2025 Mar 28; Vol. 25 (1), pp. 564. Date of Electronic Publication: 2025 Mar 28.

Tipologia de la publicació: Journal Article; Meta-Analysis; Systematic Review

Informació de la publicació: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

Terms MeSH: Carcinoma, Hepatocellular*/therapy , Carcinoma, Hepatocellular*/pathology , Carcinoma, Hepatocellular*/mortality , Carcinoma, Hepatocellular*/drug therapy , Liver Neoplasms*/therapy , Liver Neoplasms*/pathology , Liver Neoplasms*/mortality , Chemoembolization, Therapeutic*/methods , Pyridines*/therapeutic use , Pyridines*/administration & dosage , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , Immune Checkpoint Inhibitors*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Humans ; Treatment Outcome ; Combined Modality Therapy

PD-1/L1 immune checkpoint inhibitors for KRAS-mutant non-small cell lung cancer: a multicenter retrospective real-world study.

Autors: Wei K; Department of Clinical Laboratory, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, China., Sun T; Department of Respiratory and Critical Care Medicine, Changzheng Hospital, Navy Medical University, Shanghai, 200003, China., Feng X; Department of Respiratory and Critical Care Medicine, Changzheng Hospital, Navy Medical University, Shanghai, 200003, China., Chen Y; Department of Respiratory and Critical Care Medicine, Changzheng Hospital, Navy Medical University, Shanghai, 200003, China., Liu Q; Department of Clinical Laboratory, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, China. jiaodamedicine@foxmail.com., Tang H; Department of Respiratory and Critical Care Medicine, Changzheng Hospital, Navy Medical University, Shanghai, 200003, China. tanghao_0921@126.com.

Font: BMC cancer [BMC Cancer] 2025 Mar 12; Vol. 25 (1), pp. 444. Date of Electronic Publication: 2025 Mar 12.

Tipologia de la publicació: Journal Article; Multicenter Study

Informació de la publicació: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

Terms MeSH: B7-H1 Antigen*/antagonists & inhibitors , Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/genetics , Carcinoma, Non-Small-Cell Lung*/mortality , Carcinoma, Non-Small-Cell Lung*/pathology , Immune Checkpoint Inhibitors*/pharmacology , Immune Checkpoint Inhibitors*/therapeutic use , Lung Neoplasms*/drug therapy , Lung Neoplasms*/genetics , Lung Neoplasms*/mortality , Lung Neoplasms*/pathology , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , Proto-Oncogene Proteins p21(ras)*/genetics, Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Male ; Middle Aged ; Mutation ; Prognosis ; Progression-Free Survival ; Retrospective Studies

The benefit and risk of addition of PD-1/PD-L1 inhibitors to chemotherapy for advanced cervical cancer: a phase 3 randomized controlled trials based meta-analysis.

Autors: Luo D; Department of Gynecological Oncology, Ganzhou Cancer Hospital, No.19 Huayuanqian Road, Shuidong Town, Zhanggong District, Ganzhou City, Jiangxi Province, 341000, China., Yu Y; Department of Gynecological Oncology, Ganzhou Cancer Hospital, No.19 Huayuanqian Road, Shuidong Town, Zhanggong District, Ganzhou City, Jiangxi Province, 341000, China., Wang Q; Department of Gynecological Oncology, Ganzhou Cancer Hospital, No.19 Huayuanqian Road, Shuidong Town, Zhanggong District, Ganzhou City, Jiangxi Province, 341000, China., Peng T; Department of Gynecological Oncology, Ganzhou Cancer Hospital, No.19 Huayuanqian Road, Shuidong Town, Zhanggong District, Ganzhou City, Jiangxi Province, 341000, China., Li C; Department of Gynecological Oncology, Ganzhou Cancer Hospital, No.19 Huayuanqian Road, Shuidong Town, Zhanggong District, Ganzhou City, Jiangxi Province, 341000, China., Zhang W; Department of Thoracic Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, China., Huang J; Department of Gynecological Oncology, Ganzhou Cancer Hospital, No.19 Huayuanqian Road, Shuidong Town, Zhanggong District, Ganzhou City, Jiangxi Province, 341000, China. 13970111632@163.com.

Font: BMC cancer [BMC Cancer] 2025 Mar 12; Vol. 25 (1), pp. 450. Date of Electronic Publication: 2025 Mar 12.

Tipologia de la publicació: Journal Article; Meta-Analysis; Systematic Review

Informació de la publicació: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

Terms MeSH: Uterine Cervical Neoplasms*/drug therapy , Uterine Cervical Neoplasms*/mortality , Uterine Cervical Neoplasms*/pathology , Immune Checkpoint Inhibitors*/therapeutic use , Immune Checkpoint Inhibitors*/adverse effects , Immune Checkpoint Inhibitors*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , B7-H1 Antigen*/antagonists & inhibitors , Programmed Cell Death 1 Receptor*/antagonists & inhibitors, Humans ; Female ; Randomized Controlled Trials as Topic ; Clinical Trials, Phase III as Topic ; Progression-Free Survival

Efficacy and safety of PD-1/PD-L1 inhibitors for natural killer/T-cell lymphoma: a single-arm meta-analysis.

Autors: Yang J; Department of Hematology and Institute of Hematology, West China Hospital, Sichuan University, Chengdu, China., Xue X; Department of Hematology and Institute of Hematology, West China Hospital, Sichuan University, Chengdu, China., Ma Y; Department of Hematology and Institute of Hematology, West China Hospital, Sichuan University, Chengdu, China., Wang X; Department of Hematology and Institute of Hematology, West China Hospital, Sichuan University, Chengdu, China.; Department of Hematology, The Affiliated Hospital of Southwest Medical University, Luzhou, China., Xu C; Department of Hematology and Institute of Hematology, West China Hospital, Sichuan University, Chengdu, China. xucaigang@wchscu.cn.

Font: BMC cancer [BMC Cancer] 2025 Mar 03; Vol. 25 (1), pp. 385. Date of Electronic Publication: 2025 Mar 03.

Tipologia de la publicació: Journal Article; Meta-Analysis; Systematic Review

Informació de la publicació: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

Terms MeSH: Immune Checkpoint Inhibitors*/therapeutic use , Immune Checkpoint Inhibitors*/adverse effects , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , B7-H1 Antigen*/antagonists & inhibitors , Lymphoma, Extranodal NK-T-Cell*/drug therapy , Lymphoma, Extranodal NK-T-Cell*/mortality, Humans ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Treatment Outcome ; Progression-Free Survival

Increased PD-1 expression in livers associated with PD-1-antibody-induced hepatotoxicity.

Autors: Saarela M; Department of Oncology and Hematology, Oulu University Hospital, Oulu, Finland., Parviainen E; Department of Oncology and Hematology, Oulu University Hospital, Oulu, Finland.; Translational Medicine Research Unit, University of Oulu, Oulu, Finland., Lleo A; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.; Internal Medicine and Hepatology Unit, Department of Gastroenterology, IRCCS, Humanitas Research Hospital, Rozzano, Milan, Italy., di Tommaso L; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.; Department of Pathology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy., Raunio H; Department of Oncology, Tampere University Hospital, Tampere, Finland., Kankaanranta K; Department of Oncology, Tampere University Hospital, Tampere, Finland.; Tampere Cancer Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland., Vuopala K; Department of Pathology, Lapland Central Hospital, Rovaniemi, Finland., Rönkä A; Oncology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.; Cancer Center, Kuopio University Hospital, Kuopio, Finland., Nurmenniemi S; Department of Oncology and Hematology, Oulu University Hospital, Oulu, Finland.; Translational Medicine Research Unit, University of Oulu, Oulu, Finland., Kallio R; Department of Oncology and Hematology, Oulu University Hospital, Oulu, Finland., Jukkola A; Department of Oncology, Tampere University Hospital, Tampere, Finland.; Tampere Cancer Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland., Selander KS; Department of Oncology and Hematology, Oulu University Hospital, Oulu, Finland. Katriselander@icloud.com.; Translational Medicine Research Unit, University of Oulu, Oulu, Finland. Katriselander@icloud.com.

Font: BMC immunology [BMC Immunol] 2025 Jan 23; Vol. 26 (1), pp. 4. Date of Electronic Publication: 2025 Jan 23.

Tipologia de la publicació: Journal Article

Informació de la publicació: Publisher: BioMed Central Country of Publication: England NLM ID: 100966980 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2172 (Electronic) Linking ISSN: 14712172 NLM ISO Abbreviation: BMC Immunol Subsets: MEDLINE

Terms MeSH: Programmed Cell Death 1 Receptor*/metabolism , Programmed Cell Death 1 Receptor*/immunology , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , Programmed Cell Death 1 Receptor*/genetics , Chemical and Drug Induced Liver Injury*/immunology , Chemical and Drug Induced Liver Injury*/metabolism , Chemical and Drug Induced Liver Injury*/pathology , Chemical and Drug Induced Liver Injury*/etiology , Liver*/pathology , Liver*/immunology , Liver*/metabolism , Liver*/drug effects , Immune Checkpoint Inhibitors*/adverse effects, Humans ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/therapeutic use ; Male ; Female ; Middle Aged ; Aged ; Nivolumab/adverse effects ; Adult ; B7-H1 Antigen/metabolism

IL-6 and PD-1 antibody blockade combination therapy regulate inflammation and T lymphocyte apoptosis in murine model of sepsis.

Autors: Lee SI; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chungnam National University School of Medicine, Chungnam National University Hospital, 282 Munhwa-Ro, Jung-Gu, Daejeon, 35015, Republic of Korea., Kim NY; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chungnam National University School of Medicine, Chungnam National University Hospital, 282 Munhwa-Ro, Jung-Gu, Daejeon, 35015, Republic of Korea.; Cancer Research Institute, Chungnam National University, Munhwa-Ro 266, Daejeon, 35015, Republic of Korea., Chung C; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chungnam National University School of Medicine, Chungnam National University Hospital, 282 Munhwa-Ro, Jung-Gu, Daejeon, 35015, Republic of Korea., Park D; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chungnam National University School of Medicine, Chungnam National University Hospital, 282 Munhwa-Ro, Jung-Gu, Daejeon, 35015, Republic of Korea., Kang DH; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chungnam National University School of Medicine, Chungnam National University Hospital, 282 Munhwa-Ro, Jung-Gu, Daejeon, 35015, Republic of Korea., Kim DK; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chungnam National University School of Medicine, Chungnam National University Hospital, 282 Munhwa-Ro, Jung-Gu, Daejeon, 35015, Republic of Korea., Yeo MK; Department of Pathology, Chungnam National University School of Medicine, Munhwa-Ro 266, Daejeon, 35015, Republic of Korea., Sun P; College of Medicine, Research Institute for Medical Sciences, Chungnam National University, Daejeon, 35015, Republic of Korea., Lee JE; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chungnam National University School of Medicine, Chungnam National University Hospital, 282 Munhwa-Ro, Jung-Gu, Daejeon, 35015, Republic of Korea. jelee0210@cnu.ac.kr.

Font: BMC immunology [BMC Immunol] 2025 Jan 14; Vol. 26 (1), pp. 3. Date of Electronic Publication: 2025 Jan 14.

Tipologia de la publicació: Journal Article

Informació de la publicació: Publisher: BioMed Central Country of Publication: England NLM ID: 100966980 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2172 (Electronic) Linking ISSN: 14712172 NLM ISO Abbreviation: BMC Immunol Subsets: MEDLINE

Terms MeSH: Sepsis*/immunology , Sepsis*/drug therapy , Sepsis*/therapy , Interleukin-6*/antagonists & inhibitors , Interleukin-6*/immunology , Interleukin-6*/metabolism , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , Programmed Cell Death 1 Receptor*/immunology , T-Lymphocytes*/immunology , T-Lymphocytes*/drug effects , Inflammation*/immunology , Immune Checkpoint Inhibitors*/pharmacology , Immune Checkpoint Inhibitors*/therapeutic use, Animals ; Apoptosis/drug effects ; Apoptosis/immunology ; Mice ; Male ; Disease Models, Animal ; Mice, Inbred C57BL ; Cytokines/metabolism ; Spleen/immunology

The miR-23a/27a/24 - 2 cluster drives immune evasion and resistance to PD-1/PD-L1 blockade in non-small cell lung cancer.

Autors: Luo H; Department of Thoracic Surgery, Daping Hospital, Army Medical University, Chongqing, 400042, China.; School of Medicine, Chongqing University, Chongqing, 400030, China., Hu B; Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Medicine School of University of Electronic Science and Technology, Chengdu, China., Gu XR; Department of Radiology, Daping Hospital, Army Military Medical University, Chongqing, 400042, China., Chen J; School of Medicine, Chongqing University, Chongqing, 400030, China., Fan XQ; Department of Thoracic Surgery, Daping Hospital, Army Medical University, Chongqing, 400042, China., Zhang W; Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Medicine School of University of Electronic Science and Technology, Chengdu, China., Wang RT; College of Pulmonary and Critical Care Medicine, Chinese PLA General Hospital, Beijing, China., He XD; Department of Thoracic Surgery, Daping Hospital, Army Medical University, Chongqing, 400042, China., Guo W; Department of Thoracic Surgery, Daping Hospital, Army Medical University, Chongqing, 400042, China., Dai N; Cancer Center, Daping Hospital, Army Medical University, Chongqing, 400042, China., Jian D; Cancer Center, Daping Hospital, Army Medical University, Chongqing, 400042, China., Li Q; The Shapingba Hospital, Chongqing University, Chongqing, 400030, China. likunze88824@163.com., Xu CX; School of Medicine, Chongqing University, Chongqing, 400030, China. xuchengxiong@cqu.edu.cn., Jin H; Department of Thoracic Surgery, Daping Hospital, Army Medical University, Chongqing, 400042, China. jinhua12001@tmmu.edu.cn.

Font: Molecular cancer [Mol Cancer] 2024 Dec 31; Vol. 23 (1), pp. 285. Date of Electronic Publication: 2024 Dec 31.

Tipologia de la publicació: Journal Article

Informació de la publicació: Publisher: BioMed Central Country of Publication: England NLM ID: 101147698 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-4598 (Electronic) Linking ISSN: 14764598 NLM ISO Abbreviation: Mol Cancer Subsets: MEDLINE

Terms MeSH: MicroRNAs*/genetics , Carcinoma, Non-Small-Cell Lung*/genetics , Carcinoma, Non-Small-Cell Lung*/immunology , Carcinoma, Non-Small-Cell Lung*/pathology , Carcinoma, Non-Small-Cell Lung*/metabolism , B7-H1 Antigen*/genetics , B7-H1 Antigen*/metabolism , B7-H1 Antigen*/antagonists & inhibitors , Lung Neoplasms*/genetics , Lung Neoplasms*/immunology , Lung Neoplasms*/pathology , Lung Neoplasms*/metabolism , Gene Expression Regulation, Neoplastic* , Drug Resistance, Neoplasm*/genetics , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , Programmed Cell Death 1 Receptor*/genetics , Programmed Cell Death 1 Receptor*/metabolism, Humans ; Cell Line, Tumor ; Proto-Oncogene Mas ; Multigene Family ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use ; Tumor Escape/genetics ; Animals ; Immune Evasion

Identification of novel PD-1/PD-L1 small molecule inhibitors: virtual screening, synthesis and in vitro characterisation.

Autors: Wu T; Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, China.; Department of Pharmacy, Zhejiang Provincial People's Hospital BiJie Hospital, Bijie, China., Cheng H; Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, China., Sima L; Department of Oncology, The First People's Hospital of Huaihua, Huaihua, China., Wang Z; Department of Pharmacy, Guizhou Provincial People's Hospital, Guiyang, China., Ouyang W; Department of Oncology, the Affiliated Hospital of Guizhou Medical University and Cancer Hospital of Guizhou Medical University, Guiyang, China., Wang J; Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, China., Hou Y; Key Laboratory of Structure-Based Drug Design and Discovery (Shenyang Pharmaceutical University), Ministry of Education, Shenyang, PR China., Zhao D; Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, China., Liao W; Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, China., Hu C; Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, China.

Font: Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2024 Dec; Vol. 39 (1), pp. 2353711. Date of Electronic Publication: 2024 Jun 17.

Tipologia de la publicació: Journal Article

Informació de la publicació: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101150203 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1475-6374 (Electronic) Linking ISSN: 14756366 NLM ISO Abbreviation: J Enzyme Inhib Med Chem Subsets: MEDLINE

Terms MeSH: B7-H1 Antigen*/antagonists & inhibitors , B7-H1 Antigen*/metabolism , Drug Evaluation, Preclinical* , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , Programmed Cell Death 1 Receptor*/metabolism , Small Molecule Libraries*/chemistry , Small Molecule Libraries*/pharmacology, Humans ; Dose-Response Relationship, Drug ; Immune Checkpoint Inhibitors/chemistry ; Immune Checkpoint Inhibitors/pharmacology ; Ligands ; Molecular Structure ; Structure-Activity Relationship

PD-1 inhibitor combined with chemotherapy or lenvatinib in advanced gallbladder cancer: a retrospective comparative study.

Autors: Ma HY; Pharmaceutical Department, Longhua District Central Hospital, ShenZhen, China., Tai QW; Department of Hepatobiliary Surgery, Shenzhen HospitalSouthern Medical University, ShenZhen, China., Song H; Department of Hepatobiliary Surgery, Shenzhen HospitalSouthern Medical University, ShenZhen, China. songhaoamos@sina.com.

Font: BMC gastroenterology [BMC Gastroenterol] 2025 Feb 24; Vol. 25 (1), pp. 111. Date of Electronic Publication: 2025 Feb 24.

Tipologia de la publicació: Journal Article; Comparative Study

Informació de la publicació: Publisher: BioMed Central Country of Publication: England NLM ID: 100968547 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-230X (Electronic) Linking ISSN: 1471230X NLM ISO Abbreviation: BMC Gastroenterol Subsets: MEDLINE

Terms MeSH: Gallbladder Neoplasms*/drug therapy , Gallbladder Neoplasms*/pathology , Gallbladder Neoplasms*/mortality , Phenylurea Compounds*/administration & dosage , Phenylurea Compounds*/therapeutic use , Quinolines*/administration & dosage , Quinolines*/therapeutic use , Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , Immune Checkpoint Inhibitors*/therapeutic use, Humans ; Retrospective Studies ; Female ; Male ; Middle Aged ; Aged ; Adult ; Gemcitabine ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/administration & dosage ; Progression-Free Survival

Efficacy and safety of PD-1 and PD-L1 inhibitors in advanced colorectal cancer: a meta-analysis of randomized controlled trials.

Autors: Wang Z; Department of Clinical Laboratory, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China., Liu Y; Department of Clinical Laboratory, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China., Wang K; Department of Clinical Laboratory, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China., Ma L; Department of Clinical Laboratory, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China. happy_mayan2024@126.com.

Font: BMC gastroenterology [BMC Gastroenterol] 2024 Dec 18; Vol. 24 (1), pp. 461. Date of Electronic Publication: 2024 Dec 18.

Tipologia de la publicació: Journal Article; Meta-Analysis; Systematic Review

Informació de la publicació: Publisher: BioMed Central Country of Publication: England NLM ID: 100968547 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-230X (Electronic) Linking ISSN: 1471230X NLM ISO Abbreviation: BMC Gastroenterol Subsets: MEDLINE

Terms MeSH: Colorectal Neoplasms*/drug therapy , Colorectal Neoplasms*/pathology , Colorectal Neoplasms*/mortality , Immune Checkpoint Inhibitors*/administration & dosage , Immune Checkpoint Inhibitors*/adverse effects , Programmed Cell Death 1 Receptor*/antagonists & inhibitors, Humans ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/adverse effects ; B7-H1 Antigen/antagonists & inhibitors ; Progression-Free Survival ; Randomized Controlled Trials as Topic ; Treatment Outcome

PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies.

Autors: Jin M; Department of Breast Surgery (Surgical Oncology), Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, Zhejiang, China.; Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, Hangzhou, China., Fang J; Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China., Peng J; Department of General Surgery, The First People's Hospital of Jiande, Hangzhou, China., Wang X; Department of General Surgery, The Second People's Hospital of Tongxiang, Jiaxing, Zhejiang, China., Xing P; Department of Breast Surgery (Surgical Oncology), Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, Zhejiang, China.; Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, Hangzhou, China., Jia K; Department of Breast Surgery (Surgical Oncology), Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, Zhejiang, China.; Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, Hangzhou, China., Hu J; Department of Breast Surgery (Surgical Oncology), Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, Zhejiang, China.; Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, Hangzhou, China., Wang D; Department of Breast Surgery (Surgical Oncology), Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, Zhejiang, China.; Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, Hangzhou, China., Ding Y; Department of Breast Surgery (Surgical Oncology), Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, Zhejiang, China.; Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, Hangzhou, China., Wang X; Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China., Li W; Key Laboratory of Neuropharmacology and Translational Medicine of Zhejiang Province, School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China. wenluli@yahoo.com., Chen Z; Department of Breast Surgery (Surgical Oncology), Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, Zhejiang, China. chenzhigang@zju.edu.cn.; Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, Hangzhou, China. chenzhigang@zju.edu.cn.

Font: Molecular cancer [Mol Cancer] 2024 Nov 29; Vol. 23 (1), pp. 266. Date of Electronic Publication: 2024 Nov 29.

Tipologia de la publicació: Journal Article; Review; Systematic Review

Informació de la publicació: Publisher: BioMed Central Country of Publication: England NLM ID: 101147698 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-4598 (Electronic) Linking ISSN: 14764598 NLM ISO Abbreviation: Mol Cancer Subsets: MEDLINE

Terms MeSH: B7-H1 Antigen*/antagonists & inhibitors , B7-H1 Antigen*/metabolism , Breast Neoplasms*/drug therapy , Breast Neoplasms*/immunology , Breast Neoplasms*/metabolism , Breast Neoplasms*/pathology , Immune Checkpoint Inhibitors*/therapeutic use , Immune Checkpoint Inhibitors*/pharmacology , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , Programmed Cell Death 1 Receptor*/metabolism , Tumor Microenvironment*/immunology , Tumor Microenvironment*/drug effects, Animals ; Female ; Humans ; Biomarkers, Tumor ; Immunotherapy/methods ; Lymphocytes, Tumor-Infiltrating/immunology ; Lymphocytes, Tumor-Infiltrating/metabolism ; Lymphocytes, Tumor-Infiltrating/drug effects

A new strategy for immunotherapy of microsatellite-stable (MSS)-type advanced colorectal cancer: Multi-pathway combination therapy with PD-1/PD-L1 inhibitors.

Autors: Cai L; Clinical Medical College, Yangzhou University, Yangzhou, China., Chen A; Clinical Medical College, Yangzhou University, Yangzhou, China., Tang D; Department of General Surgery, Institute of General Surgery, Clinical Medical College, Yangzhou University, Northern Jiangsu People's Hospital, Yangzhou, China.

Font: Immunology [Immunology] 2024 Oct; Vol. 173 (2), pp. 209-226. Date of Electronic Publication: 2024 Mar 22.

Tipologia de la publicació: Journal Article; Review; Research Support, Non-U.S. Gov't

Informació de la publicació: Publisher: Blackwell Scientific Publications Country of Publication: England NLM ID: 0374672 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2567 (Electronic) Linking ISSN: 00192805 NLM ISO Abbreviation: Immunology Subsets: MEDLINE

Terms MeSH: Colorectal Neoplasms*/immunology , Colorectal Neoplasms*/therapy , Colorectal Neoplasms*/drug therapy , Colorectal Neoplasms*/genetics , Immune Checkpoint Inhibitors*/therapeutic use , Immune Checkpoint Inhibitors*/pharmacology , Microsatellite Instability* , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , Programmed Cell Death 1 Receptor*/immunology , Programmed Cell Death 1 Receptor*/metabolism , Immunotherapy*/methods , B7-H1 Antigen*/antagonists & inhibitors , B7-H1 Antigen*/metabolism, Humans ; Tumor Microenvironment/immunology ; Animals ; Combined Modality Therapy

Cellular mechanisms of combining innate immunity activation with PD-1/PD-L1 blockade in treatment of colorectal cancer.

Autors: Xie Q; Department of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Jinan, 250014, China., Liu X; Department of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Jinan, 250014, China., Liu R; Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China., Pan J; State Key Laboratory of Ophthalmology, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, 510060, China. panjx2@mail.sysu.edu.cn., Liang J; Department of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Jinan, 250014, China. liangjing0531@163.com.

Font: Molecular cancer [Mol Cancer] 2024 Nov 12; Vol. 23 (1), pp. 252. Date of Electronic Publication: 2024 Nov 12.

Tipologia de la publicació: Journal Article; Review

Informació de la publicació: Publisher: BioMed Central Country of Publication: England NLM ID: 101147698 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-4598 (Electronic) Linking ISSN: 14764598 NLM ISO Abbreviation: Mol Cancer Subsets: MEDLINE

Terms MeSH: Colorectal Neoplasms*/immunology , Colorectal Neoplasms*/drug therapy , Colorectal Neoplasms*/therapy , Immunity, Innate* , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , B7-H1 Antigen*/antagonists & inhibitors , Immune Checkpoint Inhibitors*/therapeutic use , Immune Checkpoint Inhibitors*/pharmacology, Humans ; Animals ; Tumor Microenvironment/immunology ; Immunotherapy/methods

Efficacy and safety of PD-1/PD-L1 inhibitors in patients with Merkel Cell Carcinoma: a systematic review and Meta-analysis.

Autors: de Moraes FCA; Federal University of Pará, R. Augusto Corrêa, 01, PA, Belém, 66075-110, Brazil. francisco.cezar2205@gmail.com., Kreuz M; Lutheran University of Brazil, Canoas, Rio Grande Do Sul, 92425-020, Brazil., de Lara ICA; Cesumar University, Maringá, Paraná, 87050-900, Brazil., Lôbo AOM; Federal University Of Pernambuco, Recife, Pernambuco, 50670-901, Brazil., Burbano RMR; Federal University of Pará, R. Augusto Corrêa, 01, PA, Belém, 66075-110, Brazil.; Ophir Loyola Hospital, Belém, Pará, 66063-240, Brazil.

Font: BMC cancer [BMC Cancer] 2024 Nov 06; Vol. 24 (1), pp. 1357. Date of Electronic Publication: 2024 Nov 06.

Tipologia de la publicació: Journal Article; Meta-Analysis; Systematic Review

Informació de la publicació: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

Terms MeSH: Carcinoma, Merkel Cell*/drug therapy , Carcinoma, Merkel Cell*/pathology , Immune Checkpoint Inhibitors*/therapeutic use , Immune Checkpoint Inhibitors*/adverse effects , Skin Neoplasms*/drug therapy , Skin Neoplasms*/mortality , Skin Neoplasms*/pathology , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , B7-H1 Antigen*/antagonists & inhibitors, Humans ; Aged ; Middle Aged ; Treatment Outcome ; Male ; Female ; Progression-Free Survival

Safety and efficacy of PD-1/PD-L1 immune checkpoint inhibitors in patients with pre-treated advanced stage malignant mesothelioma: a systematic review and meta-analysis.

Autors: Zafar A; Hameed Latif Hospital, Lahore, Pakistan., Rashid AA; Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan., Moeed A; Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan., Tahir MJ; Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan., Khan AJ; Lahore General Hospital, Lahore, Pakistan., Shrateh ON; Faculty of Medicine, Al-Quds University, Jerusalem, Palestine. oadi.shrateh@students.alquds.edu., Ahmed A; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, CA, USA.

Font: BMC cancer [BMC Cancer] 2024 Nov 05; Vol. 24 (1), pp. 1353. Date of Electronic Publication: 2024 Nov 05.

Tipologia de la publicació: Journal Article; Systematic Review; Meta-Analysis

Informació de la publicació: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

Terms MeSH: B7-H1 Antigen*/antagonists & inhibitors , Immune Checkpoint Inhibitors*/therapeutic use , Immune Checkpoint Inhibitors*/adverse effects , Mesothelioma, Malignant*/drug therapy , Mesothelioma, Malignant*/mortality , Mesothelioma, Malignant*/pathology , Programmed Cell Death 1 Receptor*/antagonists & inhibitors, Humans ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antibodies, Monoclonal, Humanized/adverse effects ; Neoplasm Staging ; Progression-Free Survival ; Treatment Outcome

PD-1/PD-L1 immune checkpoint inhibitors in the treatment of unresectable locally advanced or metastatic triple negative breast cancer: a meta-analysis on their efficacy and safety.

Autors: Wang Z; Department of General Practice Medicine, Second People's Hospital of Bengbu City, No. 302 Yan'an Road, Bengbu, Anhui Province, China., You P; Department of Biomedical Engineering, Capital Medical University, Beijing, China., Yang Z; Department of Rehabilitation Medicine, Red Cross Hospital Affiliated to Xi'an Jiaotong University, Xi'an, China., Xiao H; Department of General Practice Medicine, Nanchang University Affiliated Rehabilitation Hospital, Square South Road, Xihu District, Nanchang, Jiangxi Province, China., Tang X; Department of General Practice Medicine, Nanchang University Affiliated Rehabilitation Hospital, Square South Road, Xihu District, Nanchang, Jiangxi Province, China., Pan Y; Department of General Practice Medicine, Nanchang University Affiliated Rehabilitation Hospital, Square South Road, Xihu District, Nanchang, Jiangxi Province, China., Li X; Department of General Practice Medicine, Nanchang University Affiliated Rehabilitation Hospital, Square South Road, Xihu District, Nanchang, Jiangxi Province, China. 1154766397@qq.com., Gao F; Department of General Practice Medicine, Second People's Hospital of Bengbu City, No. 302 Yan'an Road, Bengbu, Anhui Province, China. 653837097@qq.com.

Font: BMC cancer [BMC Cancer] 2024 Oct 31; Vol. 24 (1), pp. 1339. Date of Electronic Publication: 2024 Oct 31.

Tipologia de la publicació: Journal Article; Meta-Analysis

Informació de la publicació: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

Terms MeSH: B7-H1 Antigen*/antagonists & inhibitors , B7-H1 Antigen*/metabolism , Immune Checkpoint Inhibitors*/therapeutic use , Immune Checkpoint Inhibitors*/adverse effects , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , Triple Negative Breast Neoplasms*/drug therapy , Triple Negative Breast Neoplasms*/pathology , Triple Negative Breast Neoplasms*/mortality , Triple Negative Breast Neoplasms*/immunology, Female ; Humans ; Progression-Free Survival ; Randomized Controlled Trials as Topic ; Treatment Outcome